IL1B and colitis: FICZ provides protection against colitis by reducing the production of pro-inflammatory cytokines such as IL-17, IL-1β, IL-6, TNF-α, and IFN-γ, while promoting anti-inflammatory IL-22 production from Th17 cells [88,89,92].